spacer gif spacer gif spacer gif spacer gif spacer gif
QUICK SEARCH:   [advanced]


spacer gif
     Home     Help     Feedback     Subscriptions     Archive     Search     Table of Contents    

First published online 10 October 2007
doi: 10.1242/dev.009290

Development 134, 4119-4130 (2007)
Published by The Company of Biologists 2007
This Article
Right arrow Summary Freely available
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Supplementary Material
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Langdon, Y. G.
Right arrow Articles by Conlon, F. L.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Langdon, Y. G.
Right arrow Articles by Conlon, F. L.
Social Bookmarking
Add to CiteULike   Add to Complore   Add to Connotea   Add to Del.icio.us   Add to Digg   Add to Reddit   Add to Technorati   Add to Twitter  
What's this?

SHP-2 is required for the maintenance of cardiac progenitors

Yvette G. Langdon1,2,*, Sarah C. Goetz1,2,*, Anna E. Berg2, Jackie Thomas Swanik1,2,3 and Frank L. Conlon1,2,3,{dagger}

1 Carolina Cardiovascular Biology Center, University of North Carolina, Chapel Hill, NC 27599, USA.
2 Department of Biology, Fordham Hall, University of North Carolina, Chapel Hill, NC 27599, USA.
3 Department of Genetics, Fordham Hall, University of North Carolina, Chapel Hill, NC 27599, USA.


Figure 1
View larger version (64K):
[in this window]
[in a new window]

  		Fig. 1. Inhibition of SHP-2 activity results in loss of MHC expression. Tissue explants show identical cardiac expression profiles as intact Xenopus embryos. (A) Whole-mount antibody staining of cardiac differentiation with tropomyosin (Tmy; red) or myosin heavy chain (MHC; red) antibodies as indicated, in whole embryos and cardiac explants at stages 22 (neurula), 29 (tailbud) and 37 (tadpole). (B) Whole-mount in situ hybridization for early heart markers Tbx5, Tbx20, Nkx2.5 in whole embryos and cardiac explants at stage 22, 29 and 37, as indicated. (C) MHC expression is dependent on SHP-2 activity. Whole-mount antibody staining for MHC (red) in cardiac explants taken from uninjected (control) embryos or embryos injected with Shp-2 N308D and treated with either buffer or DMSO carrier as controls or with NSC-87877 as indicated. BF, bright field.

 

Figure 2
View larger version (84K):
[in this window]
[in a new window]

  		Fig. 2. SHP-2 activity is required for the maintenance of expression of cardiac markers. (A-D) Cardiac explants isolated and cultured in DMSO or NSC-87877 beginning at stage 22. In situ hybridization performed on explants with probes specific for Nkx2.5 (A), Tbx5 (B), Tbx20-(C) and MLC1v' (D) at stages 22, 26, 29 and 33, as indicated. Black arrows denote Tbx5 expression at the leading edge of the cardiac ridge at stage 33. (E) In situ hybridization of Nkx2.5 in uninjected (control) or Shp-2 N308D-injected explants treated with DMSO or NSC-87877 beginning at stage 22, and assessed at stage 37. (F) In situ with Nkx2.5 of anterior region of whole Xenopus embryos cultured in DMSO (control) or NSC-87877. H, heart; P, pharyngeal arches.

 

Figure 3
View larger version (77K):
[in this window]
[in a new window]

  		Fig. 3. SHP-2 activity is required for pharyngeal mesoderm. (A) Schematic of tissues and rudimentary organ structures in Xenopus tissue explants. (B) Cardiac explants isolated and cultured in DMSO or NSC-87877 (NSC) beginning at stage 22. In situ hybridization performed on explants with Tbx1, Fgf8, at stages 22, 26, 29 and 33. (C) Whole-mount in situ hybridization of Endocut, Endodermin, Sox2, Ami and Xmsr at stage 37; whole embryos and cardiac explants treated with DMSO (control) or NSC-87877, as indicated.

 

Figure 4
View larger version (58K):
[in this window]
[in a new window]

  		Fig. 4. SHP-2 is required for cardiac cell survival. TUNEL staining of control cardiac explants (DMSO) and explants treated with NSC-87877. Cell death examined in explants at stages 22, 26, 29 and 33, as indicated. Red arrows denote cardiac cells, yellow arrows endodermal cells. Double in situ (red)/TUNEL (dark blue) using a Tbx5-specific probe on stage 26 explants that were cultures in DMSO or NSC-87877 from stage 22-26. Black arrow points to Tbx5-expressing cells in NSC-87877-treated explants.

 

Figure 5
View larger version (103K):
[in this window]
[in a new window]

  		Fig. 5. Blocking the cardiac cell cycle results in loss of early, but not late, cardiac markers. (A) Cardiac explants isolated and cultured in DMSO or aphidicolin to block cells in S phase beginning at stage 22 and fixed at stage 37. Whole-mount immunostaining of explants with phosphohistone H3-specific antibody (red). In situ hybridization on explants with the early cardiac markers (B) Tbx5, Tbx20, Nkx2.5, (C) Gata4, Gata5 and Gata6, (D) with the cardiac differentiation markers Hsp27 and MLC1v', and (E) by whole-mount immunostaining with the cardiac differentiation markers Tmy and MHC. (F) Explants were treated with DMSO or colchicine (Colch) to block cells in M phase of the cell cycle. In situ hybridization was performed to examine expression of Tbx5, Nkx2.5 and MLC1V', as indicated. Aph, aphidicolin; BF, bright field; pH3, phosphohistone H3-specific antibody.

 

Figure 6
View larger version (82K):
[in this window]
[in a new window]

  		Fig. 6. SHP-2 is required for the survival of proliferating cardiac cells. (A) Xenopus cardiac explants were treated with the SHP-2 inhibitor NSC-87877 beginning at stage 22, 24, 26 or 29 as indicated, cultured to stage 37 and stained with an MHC antibody (red). (B) Representative transverse sections through stage 33, 35, 42 and adult Xenopus hearts with antibodies against MHC (green) or Tmy (green), phosphohistone H3 (red) and DAPI (blue). (C) Representative transverse sections through the cardiac tissue of a DMSO-treated and an explant treated with NSC-87877 beginning at stage 29, and stained with antibodies against phosphohistone H3 (red) and Tmy (green), as assessed at stage 37. (D) Cardiac mitotic index of explants treated beginning at stage 29 with DMSO (blue bar) or NSC-87877 (magenta bar) and assessed at stage 37. Bars represent the mean mitotic index of four explants per condition. Error bars denote the standard deviation. *, a statistically significant reduction in mitotic index of NSC-87877-treated explants (P=0.0021). BF, bright field; pH3, phosphohistone H3.

 

Figure 7
View larger version (73K):
[in this window]
[in a new window]

  		Fig. 7. SHP-2 is phosphorylated and interacts with FRS in vivo. (A) Transverse cryosections through the heart of control Xenopus embryos stained with tropomyosin to mark cardiac tissue (Tmy; green), DAPI to mark cell nuclei (blue), and anti-total SHP-2, anti-phospho-542 SHP-2 or anti-phospho-580 SHP-2 (all shown in red). Arrows denote endocardial cells that are negative for SHP-2. All samples from stage 37. (B) SHP-2 interacts with FRS in vivo. Hearts from FL-HA-SHP-2-derived embryos were dissected at stage 35 and immunoprecipitated with an anti-SHP-2 antibody (+) or beads with no antibody (-). Western analysis was then performed using antibodies specific for total SHP-2, phospho-542 SHP-2 and FRS-2. Note that the level of SHP-2 phopho-542 in the input was below levels of detection.

 

Figure 8
View larger version (80K):
[in this window]
[in a new window]

  		Fig. 8. FGF functions through SHP-2 to maintain the cardiac lineage. (A) Whole-mount in situ hybridization for Tbx5, Tbx20 and Nkx2.5 or whole-mount immunostaining for MHC (red) performed on explants treated with DMSO or the FGFR1 inhibitor SU5402. (B) Explants isolated from uninjected (control) or SHP-2 N308D-injected Xenopus embryos cultured in DMSO or SU5402 and analyzed by in situ hybridization for the cardiac markers Nkx2.5 and Tbx5. (C,D) Western blot analysis of DMSO-, NSC-87877-(C) or SU5402-(D) treated explants for phosphorylated and total ERK; {alpha}-tubulin was used as a loading control. (E) Explants were cut at stage 22 and then incubated in either modified Barth's solution (MBS) or SU5402 until stage 35. Either endogenous SHP-2 was immunoprecipitated (IP) or explants were lysed (IB) and western analysis performed as in Fig. 7B.

 

Add to CiteULike CiteULike   Add to Complore Complore   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati   Add to Twitter Twitter    What's this?



© The Company of Biologists Ltd 2007